The Gut and Skin Microbiome and Its Association with Aging Clocks

Do you know what the aging clock is?

In the paper of Mildred Min, Caitlin Egli and Raja Sivamani M.D., M.S., A.P. you can learn about these predictive models of biological age derived from age-related changes, such as epigenetic changes, blood biomarkers, and, more recently, the microbiome.

Recent studies have shown that human microbiomes may predict aging.

In this narrative review, they discuss how the gut and skin microbiomes influence aging clocks as well as clarify the distinction between chronological and biological age.

IJMS | Free Full-Text | The Gut and Skin Microbiome and Its Association with Aging Clocks (mdpi.com)



Reusable Cyclodextrin-Mediated Electrochemical Sensor in Automated Flow Cell for Cortisol Detection

Today’s cyclodextrin is detecting cortisol.

It comes from the oven of Ferdows Sajedi and Jeffrey Halpern at University of New Hampshire. The focus is on using beta-cyclodextrin (βCD) to electrochemically detect cortisol employing an automated flow cell system.

The ultimate goal is to optimize sensor stability, sensitivity, and reproducibility, contributing to the advancement of cortisol detection with the automated cyclodextrin-mediated biosensors.

Reusable Cyclodextrin-Mediated Electrochemical Sensor in Automated Flow Cell for Cortisol Detection – IOPscience

University of the Witwatersrand and CarboHyde Zrt Announce Strategic Collaboration to Develop Breast Cancer Therapeutic

Johannesburg, South Africa, and Budapest, Hungary – [28/08/2024] – The University of the Witwatersrand (WITS), a leading research institution in South Africa, and CarboHyde Zrt, a pharmaceutical company based in Hungary, have entered into a strategic collaboration to advance the development of a novel breast cancer therapeutic. This partnership aims to accelerate the development of this asset further while securing funding opportunities within Europe and ensuring the successful progress of this promising therapeutic from research to market.

The collaboration between WITS and CarboHyde will be executed in multiple phases: first, finishing the preclinical studies, and later, starting clinical trials together or with other partners.

This collaboration marks a significant milestone in the fight against breast cancer, combining the strengths of two innovative organizations across continents. By pooling their resources, expertise, and networks, WITS and CarboHyde aim to bring this cutting-edge therapeutic to market, benefiting patients and healthcare systems worldwide.

For more information, please contact CarboHyde at info@carbohyde.com


About the University of the Witwatersrand: The University of the Witwatersrand (WITS) is a leading research-intensive institution based in Johannesburg, South Africa. WITS is dedicated to advancing knowledge through impactful research and is recognized globally for its contributions to science and innovation.

About CarboHyde Zrt: CarboHyde is a pharmaceutical company based in Budapest, Hungary, specializing in carbohydrate chemistry, including cyclodextrins. CarboHyde focuses on creating innovative solutions and collaborating with partners worldwide to bring breakthrough technologies to market in the pharmaceutical arena.

Oculis closes Phase 3 eye drop trial due to ‘administrative error’ from third party

Today’s cyclodextrin is some news fresh from Oculis‘s oven about the lead drug OCS-01, which is delivered with a unique and proprietary cyclodextrin technology.

The company reported in its second-quarter financial filing that a Phase 3 trial for Oculis’ lead eye drop candidate will be shut down due to an administrative error.

The company added, however, that it had a pre-NDA meeting with the FDA this month, where it got the go-ahead to still file for approval in the first quarter of next year. According to Oculis, the agency confirmed the data it already has from its first Phase 3 trial and a Phase 2 trial, alongside safety data from other studies in ocular surgery and diabetic macular edema, are enough to support an NDA submission.

I’m so happy that this unfortunate event does not seem to hold back the progress of this amazing drug and technology.

If OCS-01 is approved, it would be the first daily and preservative-free steroid for treating inflammation and pain following ocular surgery.

Risperidone-cyclodextrin complex reservoir combined with hydrogel-forming microneedle array patches for enhanced transdermal delivery

Today’s cyclodextrin is about one of favourite novel DDS: microneedles!

Hydrogel-forming microneedle array patches (HFMAPs) are microneedles that create microconduits upon insertion and swelling in the skin, potentially allowing prolonged drug delivery without generating sharps waste.

To enhance the aqueous solubility and successfully deliver risperidone hydroxypropyl-beta-cyclodextrin (HP-β-CD) and hydroxypropyl-gamma-cyclodextrin (HP-γ-CD) were utilized and their performance was tested using phase solubility studies.

For a 1-day application, HFMAPs showed greater systemic exposure to RIS compared to intramuscular control and exposure was extended to 5 days.

In conclusion, HFMAPs could serve as an alternative for delivering RIS in a sustained manner, potentially improving the treatment of schizophrenia.
Risperidone-cyclodextrin complex reservoir combined with hydrogel-forming microneedle array patches for enhanced transdermal delivery – ScienceDirect

Great work from Queen’s University Belfast and Ryan DonnellyLalitkumar Vora, PhD teams.

World-first lung cancer vaccine trials launched across seven countries

Doctors have begun trialing the world’s first mRNA lung cancer vaccine in patients, as experts hailed its “groundbreaking” potential to save thousands of lives.

The phase 1 clinical trial, the first human study of BNT116, has launched across 34 research sites in seven countries: the UK, US, Germany, Hungary, Poland, Spain and Turkey.

As a company working on drug delivery solutions for oligonucleotides, we hold our breath and watch carefully how this goes.

World-first lung cancer vaccine trials launched across seven countries | Lung cancer | The Guardian

Fascinating taste-masking matryoshka doll drug delivery systems are proposed by Bayer

The compositions comprise an active pharmaceutical ingredient and the multi-component taste-masking physical barrier comprising one or more of an ion exchange resin, a cyclodextrin, and a hydrocolloid. The patent: WO2024159161 TASTE-MASKING WITH A MULTI-COMPONENT PHYSICAL BARRIER (wipo.int)
BRADLEY, Reginald
Debanjan (Deb) Das
MEISEL, Gerald
Tejas Kekatpure

If you are interested in creating similar solutions with cyclodextrins, here you can learn more: Formulation development – www.carbohydesolutions.com



Preparing for a busy September

Full team

Unbelievable, but it has been 191 days since we had the full CarboHyde team together in person.

After completing 3 Bicyclos HEurope secondments, now we will enjoy a few months together before we depart again in the fall.

Now that Kristof is back too, he focuses on finishing his PhD and just tackled his practical defence.

CarboHyde team

Roquette – CarboHyde webinar vol 3

Our next free webinar, titled “Cyclodextrin formulations: The Journey from the Benchtop to the Patients” brings together experts who will guide us through the milestones of this remarkable journey.

Event Overview: Join us for an illuminating webinar that traces the evolution of cyclodextrin-based drug delivery systems—from laboratory research to real-world patient care. Our esteemed speakers will explore key aspects of this journey, highlighting breakthroughs, challenges, and the promise of cyclodextrins in improving therapeutic outcomes.

Link for registration: https://www.congress-service.hu/rendezveny/cyclodextrinwebinar2024

Time&Date: September 26., 2024, 3 pm – 5 pm (CEST, Budapest time)

Cyclodextrin Workshop

We still have a few seats open for this fantastic event we are organizing together with Eötvös Loránd University under the frame of the Bicyclos HEurope project.

A 2,5-day workshop in September 2024 in the lovely Budapest, dealing with New approaches to sustainable synthetic chemistry of carbohydrates and derivatives.

Our target audience are undergrad and PhD students, yet industry professionals and any carbohydrate/cyclodextrin beginners are more than welcome. Learn more about the event: https://lnkd.in/gbHUg-DX

Register: https://lnkd.in/dZsis8UW

It will be stunning!